At I-Motion, enrollments in the study ESSENCE started on August 10th. This phase III trial aims to evaluate safety and efficacy of SRP-4045 and SRP-4053 in boys aged 7 to 13 with Duchenne muscular dystrophy.
> More about ESSENCE
> More about current trials at I-Motion